Teleflex Incorporated
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Teleflex Incorporated (TFX). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Americas | $1.47B 57.7% | $1.66B 59.1% · +13.3% | $1.93B 69.0% · +16.1% | $1.18B 68.9% · -38.7% | $1.16B 68.1% · -2.0% | $1.28B 64.2% · +10.6% |
| EMEA | $584.9M 23.1% | $606.8M 21.6% · +3.8% | $558.4M 20.0% · -8.0% | $317.0M 18.5% · -43.2% | $340.3M 20.0% · +7.3% | $472.4M 23.7% · +38.8% |
| Asia | $267.0M 10.5% | $297.8M 10.6% · +11.5% | $306.3M 11.0% · +2.9% | $214.8M 12.5% · -29.9% | $202.3M 11.9% · -5.8% | $241.1M 12.1% · +19.2% |
| OEM | $220.2M 8.7% | $245.7M 8.7% · +11.5% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by region
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| UNITED STATES | $1.57B 61.8% | $1.77B 63.0% · +12.9% | $1.79B 64.0% · +1.0% | $1.11B 64.6% · -38.0% | $1.08B 63.5% · -2.5% | $1.18B 59.3% · +9.5% |
| Europe | $646.6M 25.5% | $665.0M 23.7% · +2.8% | $622.3M 22.3% · -6.4% | $330.1M 19.3% · -47.0% | $347.9M 20.5% · +5.4% | $484.7M 24.3% · +39.3% |
| Asia Pacific | $230.3M 9.1% | $263.0M 9.4% · +14.2% | $270.7M 9.7% · +2.9% | $187.9M 11.0% · -30.6% | $179.6M 10.6% · -4.5% | $218.0M 10.9% · +21.4% |
| All other | $93.2M 3.7% | $112.1M 4.0% · +20.3% | $111.5M 4.0% · -0.5% | $87.5M 5.1% · -21.5% | $92.7M 5.5% · +5.9% | $108.1M 5.4% · +16.6% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Revenue by product line
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Vascular access | $657.7M 25.9% | $700.2M 24.9% · +6.5% | $683.6M 24.5% · -2.4% | $841.1M 49.1% · +23.0% | $903.5M 53.2% · +7.4% | $917.7M 46.1% · +1.6% |
| Interventional | $382.4M 15.1% | $427.5M 15.2% · +11.8% | $445.0M 15.9% · +4.1% | $407.3M 23.8% · -8.5% | $397.3M 23.4% · -2.4% | $647.8M 32.5% · +63.0% |
| Surgical | $317.2M 12.5% | $377.8M 13.4% · +19.1% | $392.9M 14.1% · +4.0% | $388.3M 22.7% · -1.2% | $404.9M 23.8% · +4.3% | $418.2M 21.0% · +3.3% |
| Other | $367.3M 14.5% | $336.6M 12.0% · -8.4% | $285.1M 10.2% · -15.3% | $75.8M 4.4% · -73.4% | -$6.2M -0.4% · -108.2% | $9.0M 0.5% · +246.3% |
| Anesthesia | $302.3M 11.9% | $380.1M 13.5% · +25.8% | $388.9M 13.9% · +2.3% | – | – | – |
| Interventional urology | $290.0M 11.4% | $341.7M 12.2% · +17.8% | $322.8M 11.6% · -5.5% | – | – | – |
| OEM | $220.2M 8.7% | $245.7M 8.7% · +11.5% | $272.6M 9.8% · +11.0% | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.